Individual and population benefits of daily aspirin therapy a proposal for personalizing national guidelines

Circulation: Cardiovascular Quality and Outcomes

Volumn 4, Issue 3, 2011, Pages 268-275

  Sussman, Jeremy B ^a,b   Vijan, Sandeep ^a,b   Choi, Hwajung ^b   Hayward, Rodney A ^a,b  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aspirin; Cardiovascular pharmacology; Chronic ischemic; Decision making; Heart disease; Prevention; Primary prevention; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DECISION MAKING; DRUG USE; FEMALE; HEALTH SURVEY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; DECISION MAKING; FEMALE; HEALTH PLANNING GUIDELINES; HUMANS; MALE; MIDDLE AGED; PATIENT PARTICIPATION; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 79959748960     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.959239     Document Type: Article

References (19)

1. Arias E United States life tables, 2004 Natl Vital Stat Rep 2007;56:1-39.
2. Heron MDeaths: leading causes for 2004.Natl Vital Stat Rep 2007;56:1-95.
3. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong YHeart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-486.
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WBPrediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847. (Pubitemid 28213628)
5. Anderson KM, Odell PM, Wilson PW, Kannel WBCardiovascular disease risk profilesAmerican heart journal1991;121:293-298.
6. Sturgeon JD, Folsom AR, Longstreth WT, Jr., Shahar E, Rosamond WD, Cushman MRisk factors for intracerebral hemorrhage in a pooled prospective study Stroke; a journal of cerebral circulation 2007;38:2718-2725. (Pubitemid 47494009)
7. Saini SD, Schoenfeld P, Fendrick AM, Scheiman JCost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Archives of internal medicine 2008;168:1684-1690; discussion 1691.
8. Rockall TA, Logan RF, Devlin HB, Northfield TCIncidence of and mortality from acute upper gastrointestinal haemorrhage in the United KingdomSteering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage BMJ (Clinical research ed) 1995;311:222-226.
9. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 2009;373:1849-1860.
10. Bronnum-Hansen H, Jorgensen T, Davidsen M, Madsen M, Osler M, Gerdes LU, Schroll M Survival and cause of death after myocardial infarction: the Danish MONICA study J Clin Epidemiol 2001;54:1244-1250. (Pubitemid 34002977)
11. Donahue RP, Goldberg RJ, Chen Z, Gore JM, Alpert JSThe influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective J Clin Epidemiol 1993;46:245-252. (Pubitemid 23107072)
12. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, Stewart-Wynne EG Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke; a journal of cerebral circulation 2000;31:2080-2086.
13. Bronnum-Hansen H, Davidsen M, Thorvaldsen PLong-term survival and causes of death after strokeStroke; a journal of cerebral circulation2001;32:2131-2136. (Pubitemid 32868112)
14. Fogelholm R, Murros K, Rissanen A, Avikainen SLong term survival after primary intracerebral haemorrhage: a retrospective population based studyJ Neurol Neurosurg Psychiatry2005;76:1534-1538. (Pubitemid 41531701)
15. Pignone M, Earnshaw S, Tice JA, Pletcher MJAspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Annals of internal medicine 2006;144:326-336. (Pubitemid 46768187)
16. Kent DM, Hayward RA Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. Jama 2007;298:1209-1212. (Pubitemid 47403108)
17. Hayward RA, Kent DM, Vijan S, Hofer TPReporting clinical trial results to inform providers, payers, and consumers. Health affairs (Project Hope) 2005;24:1571-1581.
18. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DLAspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. Jama 2006;295:306-313.
19. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JEA randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. The New England journal of medicine 2005;352:1293-1304.